Keyword: Tecentriq

Tecentriq has stumbled again. The I-O drug, teamed with fellow Roche med Cotellic, fell short in a colorectal cancer test against Bayer's Stivarga.

Roche’s Tecentriq-Avastin-chemo combo may have just scored a quicker trip into the first-line lung arena, where a Merck rivalry awaits.

Roche says it's in the midst of one of the most successful multiple sclerosis launches ever—and MS has had some doozies.

Roche may have just hit a snag in its bid to push a combination of Tecentriq and Cotellic into metastatic colorectal cancer.

After a previous rejection and a discount offer, Roche's immunotherapy Tecentriq snagged an OK from England's influential cost-effectiveness watchdogs.

Roche is back with more survival data for its Tecentriq-Avastin cocktail—and it’s more important survival data, too.

Thanks to some new data, Roche has a chance to differentiate itself in the immuno-oncology market for lung cancer. Can it translate into significant sales?

AstraZeneca's Imfinzi won't have its first-line lung cancer data till later than expected, and at a time when Merck's Keytruda is racing ahead.

Facing tough competition for Tecentriq in bladder cancer, Roche plans to test the drug in combination with Tesaro's PARP inhibitor Zejula.